Innovative Antithrombin III Diagnostic Testing Technologies and Emerging Markets
Innovative Antithrombin III Diagnostic Testing Technologiesand Emerging MarketsReport Details:Published:November 2012No. of Pages: 197Price: Single User License – US$3850This report contains 197 pages, 8 tables and presents a detailed analysis of the AT III testingmarket in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinicalsignificance and current laboratory practice, as well as 5- and 10-year test volume forecasts bycountry and market segment.The growing cost-containment pressures in major industrialized nations and continuedtechnological advances will radically change coagulation testing practice during the next ten years.New specific and sensitive markers of hemostasis will be increasingly used on automatedinstrumentation. Coagulation testing in general, and AT III testing specifically, will become morestandardized, offering opportunities for quality control products and services. Moreover, thecontinuing contraction of the hospital system and technological advances will facilitatedecentralization of the AT III testing closer to the patient, creating additional opportunities andchallenges for suppliers.The report examines market applications of chromogenic substrates, monoclonal antibodies,immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews featuresand operating characteristics of automated analyzers; profiles leading suppliers and recent marketentrants developing innovative technologies and products; and identifies alternative marketpenetration strategies and entry barriers/risks.Get your copy of this report @http://www.reportsnreports.com/reports/207873-innovative-antithrombin-iii-diagnostic-testing-technologies-and-emerging-markets-.htmlMajor points covered in Table of Contents of this report includeTable of ContentsI. IntroductionII. Worldwide Market and Technology OverviewA. IntroductionB. Antithrombin III: Clinical Significance: Clinical Significance and Current Laboratory Procedures
10. BiosensorsIII. France: Test Volume Forecasts by Market SegmentIV. Germany: Test Volume Forecasts by Market SegmentV. Italy: Test Volume Forecasts by Market SegmentVI. Japan: Test Volume Forecasts by Market SegmentVII. Spain: Test Volume Forecasts by Market SegmentVIII. UK: Test Volume Forecasts by Market SegmentIX. USA: Test Volume Forecasts by Market SegmentX. Design Criteria For Decentralized Testing ProductsXI. Alternative Market Penetration StrategiesA. Internal DevelopmentB. Collaborative ArrangementsC. University ContractsD. Distribution Strategies for Decentralized Testing Markets1. Marketing Approaches2. Product Complexity3. Customer Preference4. Established Suppliers5. Emerging Suppliers6. Major Types Of Distributors7. Market SegmentationXII. Potential Market Entry Barriers and RisksA. Market MaturityB. Cost ContainmentC. CompetitionD. Technological Edge and LimitationsE. Patent ProtectionF. Regulatory ConstraintsG. Decentralized Testing Market ChallengesXIII. Competitive AssessmentsAbbott
American DiagnosticaAvocet MedicalAxis-ShieldBeckman CoulterBecton DickinsonBio/Data CorporationBiositeChrono-LogCorgenix MedicalDiagnostica StagoHelena LaboratoriesHYPEN BioMedInstrumentation LaboratoryITCNanogenRocheSiemensSiencoSysmexThermo FischerTrinity BiotechZyCareList of TablesMajor Companies Developing or Marketing Antithrombin III TestsFranceAntithrombin III Test Volume Forecasts by Market SegmentGermanyAntithrombin III Test Volume Forecasts by Market SegmentItalyAntithrombin III Test Volume Forecasts by Market SegmentJapanAntithrombin III Test Volume Forecasts by Market SegmentSpainAntithrombin III Test Volume Forecasts by Market SegmentU.K.Antithrombin III Test Volume Forecasts by Market SegmentU.S.A.Antithrombin III Test Volume Forecasts by Market Segment
Contact: firstname.lastname@example.org for more information.